Literature DB >> 33077921

Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.

Kyohei Yugawa1,2, Shinji Itoh3, Tomoharu Yoshizumi1, Norifumi Iseda1, Takahiro Tomiyama1, Takeo Toshima1, Noboru Harada1, Kenichi Kohashi2, Yoshinao Oda2, Masaki Mori1.   

Abstract

Tumor microvessel density (MVD) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (ICC). Tumor-infiltrating lymphocytes (TILs) are also key components of the tumor microenvironment that play important roles in ICC progression. This study aimed to clarify the relationships between the MVD and immune status and prognosis in patients with ICC. Immunohistochemical staining for cluster of differentiation 34 (CD34), cluster of differentiation 8 (CD8), forkhead box protein P3 (Foxp3), and programmed death-ligand 1 (PD-L1) was performed. The relationships between the MVD and clinicopathological characteristics and outcomes were analyzed. Additionally, the correlations between the MVD, CD8+ and Foxp3+ TIL counts, and PD-L1 expression were evaluated. One hundred ICC patients were classified into high (n = 50) and low (n = 50) MVD groups. The serum platelet and carbohydrate antigen 19-9 levels were higher in the low MVD group than in the high MVD group (P = 0.017 and P = 0.008, respectively). The low MVD group showed a significantly larger tumor size (P = 0.016), more frequent microvascular invasion (P = 0.001), and a higher rate of intrahepatic (P = 0.023) and lymph node (P < 0.001) metastasis than the high MVD group. Moreover, the MVD showed a high positive correlation with CD8+ TILs (r = 0.754, P < 0.001) and a negative correlation with Foxp3+ TILs (r = -0.302, P = 0.003). In contrast, no significant correlation was observed between the MVD and PD-L1 expression in cancer cells (P = 0.817). Patients with low MVDs had a significantly worse prognosis than those with high MVDs. Furthermore, multivariable analyses revealed that a low MVD influenced recurrence-free survival. A decreased intratumoral MVD might predict ICC patient outcomes. Tumor microvessels might be associated with ICC progression, possibly by altering TIL recruitment.

Entities:  

Year:  2020        PMID: 33077921     DOI: 10.1038/s41379-020-00702-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

1.  Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells.

Authors:  Jiehong Zeng; Zhengkai Liu; Shuwen Sun; Jianhong Xie; Li Cao; Pin Lv; Shengdan Nie; Bao Zhang; Bowen Xie; Siyuan Peng; Bo Jiang
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

2.  Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.

Authors:  S Itoh; K Yugawa; M Shimokawa; S Yoshiya; Y Mano; K Takeishi; T Toshima; Y Maehara; M Mori; T Yoshizumi
Journal:  BJS Open       Date:  2019-04-29
  2 in total
  8 in total

1.  Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?

Authors:  Juan Wang; Emilien Loeuillard; Gregory J Gores; Sumera I Ilyas
Journal:  Expert Opin Ther Targets       Date:  2021-12-03       Impact factor: 6.797

Review 2.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

3.  Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.

Authors:  Kyohei Yugawa; Shinji Itoh; Norifumi Iseda; Takeshi Kurihara; Yoshiyuki Kitamura; Takeo Toshima; Noboru Harada; Kenichi Kohashi; Shingo Baba; Kousei Ishigami; Yoshinao Oda; Tomoharu Yoshizumi; Masaki Mori
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

4.  Radiomics Analysis of Contrast-Enhanced CT for the Preoperative Prediction of Microvascular Invasion in Mass-Forming Intrahepatic Cholangiocarcinoma.

Authors:  Fei Xiang; Shumei Wei; Xingyu Liu; Xiaoyuan Liang; Lili Yang; Sheng Yan
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

5.  PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.

Authors:  Ahmad Alhesa; Heyam Awad; Sarah Bloukh; Mahmoud Al-Balas; Mohammed El-Sadoni; Duaa Qattan; Bilal Azab; Tareq Saleh
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

6.  Impact of JMJD6 on intrahepatic cholangiocarcinoma.

Authors:  Yukiko Kosai-Fujimoto; Shinji Itoh; Kyohei Yugawa; Takasuke Fukuhara; Daisuke Okuzaki; Takeo Toshima; Noboru Harada; Yoshinao Oda; Tomoharu Yoshizumi; Masaki Mori
Journal:  Mol Clin Oncol       Date:  2022-06-23

Review 7.  Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Authors:  John E Mullinax; Michael E Egger; Martin McCarter; Bradley J Monk; Eric M Toloza; Susan Brousseau; Madan Jagasia; Amod Sarnaik
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

8.  PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.

Authors:  Takahiro Hongo; Hidetaka Yamamoto; Rina Jiromaru; Ryuji Yasumatsu; Ryosuke Kuga; Yui Nozaki; Kazuki Hashimoto; Mioko Matsuo; Takahiro Wakasaki; Akihiro Tamae; Kenichi Taguchi; Satoshi Toh; Muneyuki Masuda; Takashi Nakagawa; Yoshinao Oda
Journal:  Mod Pathol       Date:  2021-07-03       Impact factor: 7.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.